CERT Certara

Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024

Certara to Report Second Quarter 2024 Financial Results on August 6th, 2024

RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.

Investors interested in listening to the conference call are required to  It is recommended to register at least one day in advance.

A live and archived webcast of the event will be available on the “Investors” section of the Certara website at .

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Alyssa Horowitz



EN
02/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE

Certara to Report Fourth Quarter and Full Year 2025 Financial Results ...

Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025 RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to . It is recommended to register at least one day in adva...

 PRESS RELEASE

Certara Reports Third Quarter 2025 Financial Results

Certara Reports Third Quarter 2025 Financial Results  Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 m...

 PRESS RELEASE

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara Automates Scientific Workflows with Phoenix® Cloud New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL St...

 PRESS RELEASE

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: UBS Global Healthcare ConferenceDate and Time: Tuesday, November 11th 2025 at 2:00PM ET Jefferies Global Healthcare Conference in LondonDate and Time: Tuesday, November 18th 2025 at 10:30AM GMT Stephens Annual Investment ConferenceDate and Time: Tuesday, November 18th 2025 at 1:00PM CT Live webcasts for each ...

 PRESS RELEASE

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Certara Expands Biosimulation Market with AI-Driven QSP Platform Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution. QSP has rapidly become a cornerstone of modern drug discovery and development with QSP-based FDA submissions having nearly doubled every 1...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch